Kumquat Biosciences
PrivateLast Round
Strategic
Jul 29, 2021
Est. Valuation
$304.89M
Total Funding Raised
$175.9M
Company Overview
Kumquat Biosciences operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Strategic round in July 2021.
Kumquat Biosciences is a biotechnology company that develops small-molecule immunotherapies and oncology medicines to treat cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Kumquat Biosciences Comparables
Compare Kumquat Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Quanta Therapeutics | 87% | |
| Tyligand Bioscience | 86% | |
| BridgeBio Pharma, Inc. | 82% |
For institutional investors. Book with your work email.
Kumquat Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Jul 29, 2021 | ||||
| Series A Extension | Feb 5, 2021 | ||||
| Series A | Sep 8, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Kumquat Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series A, Strategic, Series A Extension |
| Roche Venture Fund | Series A, Strategic, Series A Extension |
| OrbiMed | Series A, Strategic, Series A Extension |
| Roche Venture Fund | Series A, Series A Extension |
| Lilly Asia Ventures | Series A, Strategic, Series A Extension |
| Lilly Asia Ventures | Series A, Series A Extension |
| HongShan Capital Group (HSG) | Series A, Strategic, Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 13, 2025
Developing KRAS G12D candidate in partnership with Bayer.
- Aug 13, 2025
Partnered with Bayer to co-develop an oncology candidate.
For institutional investors. Book with your work email.
Kumquat Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Kumquat Biosciences's valuation, stock price, and market status.
Is Kumquat Biosciences a public or private company?
Kumquat Biosciences is a private company.
What is the current stock price of Kumquat Biosciences?
Kumquat Biosciences is a private company, so its shares have no public market price. Caplight tracks Kumquat Biosciences's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Kumquat Biosciences worth (valuation)?
Kumquat Biosciences's valuation is estimated at $304.9M based on funding round data.
Can I buy Kumquat Biosciences stock?
Kumquat Biosciences shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Kumquat Biosciences's last funding round?
Kumquat Biosciences's most recent funding round was Strategic on July 29, 2021.
Who are the main investors in Kumquat Biosciences?
Key investors in Kumquat Biosciences include EcoR1 Capital, Roche Venture Fund, OrbiMed, Roche Venture Fund, Lilly Asia Ventures.
Will Kumquat Biosciences IPO soon?
No public IPO plans have been announced for Kumquat Biosciences.
How can I track Kumquat Biosciences secondary market activity?
Caplight tracks bids, offers, and trades in Kumquat Biosciences's shares on secondary markets.